Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands
| Autor: | Usman Iqbal, F. Joulain, S. H. Goey, N. Muszbek, D.R. Ferry, S. Naoshy, Dara Stein, K. A. Payne |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Male medicine.medical_specialty Palliative care Organoplatinum Compounds Cross-sectional study Pain Antineoplastic Agents Anxiety Quality of life EQ-5D Internal medicine Surveys and Questionnaires Activities of Daily Living Medicine Humans Adverse effect Depression (differential diagnoses) Netherlands Performance status business.industry Depression Palliative Care Gastroenterology Middle Aged United Kingdom Oxaliplatin Cross-Sectional Studies Disease Progression Quality of Life Observational study Female business Colorectal Neoplasms |
| Zdroj: | International journal of colorectal disease. 29(10) |
| ISSN: | 1432-1262 |
| Popis: | This study aimed to elicit EuroQol Quality of Life 5-Dimensions (EQ-5D) utility values from patients with second-line metastatic colorectal cancer (mCRC) pre- and post-progression. A cross-sectional study was conducted in five hospitals in the Netherlands and the UK. Patients with mCRC were eligible if prescribed a second or subsequent line of therapy or best supportive care (BSC), received prior oxaliplatin in first-line therapy, and had Eastern Cooperative Oncology Group (ECOG) performance status scores of 0–2 at second-line initiation. Patients completed the EuroQol Quality of Life 5-Dimensions 3-levels (EQ-5D-3L) questionnaire and were categorized as pre- or post-progression. Chart data including patient demographics, clinical history, prior/current treatments and serious adverse events (SAEs) were collected. Mean utilities were estimated; uni- and multivariate analyses were conducted. Seventy-five patients were enrolled; 42 were pre-progression defined as second line or third line following an AE on second line and 33 were post-progression defined as third or subsequent therapy lines or BSC. Patient/disease characteristics and number of SAEs were similar between cohorts. Mean utility scores were 0.741 (SD = 0.230) and 0.731 (SD = 0.292) for pre- and post-progression cohorts, respectively. Compared to pre-progression, more patients reported increased anxiety/depression (36 vs. 12 %) and fewer problems with daily activities (64 vs. 38 %) post-progression. More patients pre-progression were on active treatment at enrolment (83 vs. 42 %) compared to post-progression. This is the first real-world study to collect utilities for patients with second-line mCRC pre- and post-disease progression. Utility values were similar pre- and post-progression. To further explore the effect of radiological progression on utilities, longitudinal research is required that includes patients in palliative care centres. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink